Nastech to concentrate on RNAi technology, change name

06/10/2008 | Boston Globe (tiered subscription model), The

Nastech Pharmaceutical Co. announced that it will change its name to mdRNA, effective June 23, as it shifts its focus to RNAi technology. RNAi-based therapies, also called gene-silencing treatments, will be available sooner than expected, driven by industry interest and the technology's rapid progression, said incoming mdRNA CEO J. Michael French.

View Full Article in:

Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI